OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Price, News & Analysis $0.16 0.00 (0.00%) As of 06/25/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Arch Therapeutics Stock (OTCMKTS:ARTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arch Therapeutics alerts:Sign Up Key Stats Today's Range$0.16▼$0.1650-Day Range N/A52-Week Range$0.16▼$1.57VolumeN/AAverage Volume4,068 shsMarket Capitalization$762.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arch Therapeutics, Inc. (OTCMKTS: ARTH) is a development‐stage medical device company focused on applying its proprietary synthetic self‐assembling peptide technology to hemostasis, sealant and antimicrobial applications. Its platform is designed to rapidly form protective barriers in wet surgical and trauma environments without requiring external energy, with the goal of improving patient outcomes and reducing procedure times. The company’s lead product candidates utilize its AC5™ formulation, which is being evaluated for a range of clinical indications including bleeding control during open and minimally invasive surgeries, emergency trauma care and interventional radiology procedures. Arch is also exploring advanced applications of its peptide technology in tissue regeneration and infection prevention. Headquartered in Framingham, Massachusetts, the company primarily operates within the United States while pursuing regulatory approvals in key international markets. Arch collaborates with clinical partners and contract manufacturers to advance its pipeline through preclinical and clinical studies, as well as to scale for potential commercialization. Established in the late 2000s, Arch has evolved from a research‐driven enterprise to a product development organization. Its leadership team comprises professionals with backgrounds in medical device engineering, clinical research and regulatory affairs, positioning the company to navigate the complexities of developing next‐generation surgical and trauma care solutions.AI Generated. May Contain Errors. Read More Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTH Stock News HeadlinesArch Therapeutics Inc. (ARTH) Product Pipeline Analysis, 2025 UpdateAugust 9, 2025 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)October 1, 2024 | globenewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.June 26 at 1:00 AM | Profits Run (Ad)Chicago biotech-focused VC firm Arch Venture Partners closes $3 billion fundSeptember 27, 2024 | bizjournals.comArch Therapeutics, Inc. (ARTH)August 21, 2024 | finance.yahoo.comArch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug ToxinsAugust 2, 2024 | tmcnet.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)May 6, 2024 | globenewswire.comArch Therapeutics Secures $750K Prepayment for StockFebruary 8, 2024 | msn.comSee More Headlines ARTH Stock Analysis - Frequently Asked Questions How have ARTH shares performed this year? Arch Therapeutics' stock was trading at $0.1608 on May 30, 2026. Since then, ARTH stock has increased by 0.0% and is now trading at $0.1608. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its quarterly earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), GE Aerospace (GE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings7/23/2020Today6/26/2026Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees10Year Founded2006Profitability EPS (Trailing Twelve Months)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.98 million Net Margins-8,257.70% Pretax Margin-8,257.70% Return on EquityN/A Return on Assets-730.22% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.01 Sales & Book Value Annual Sales$80 thousand Price / Sales9.53 Cash FlowN/A Price / Cash FlowN/A Book Value($2.43) per share Price / Book-0.07Miscellaneous Outstanding Shares4,742,000Free Float4,529,000Market Cap$762.51 thousand OptionableNot Optionable Beta4.02 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:ARTH) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersThe EPA just put a kill switch on Elon’s empireA federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredSell Tesla, Buy the New King of FSD CarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...Chaikin Analytics | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredGrab it and keep itSimple Options Trading For Beginners is currently available as a free download - a guide normally priced at $2...Profits Run | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arch Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
